Detalles de la búsqueda
1.
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
Breast Cancer Res Treat
; 193(1): 95-103, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35212906
2.
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(10): 1269-1282, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32861273
3.
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Breast
; 74: 103681, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38377732
4.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 379(9816): 633-40, 2012 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-22257673
5.
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Radiol Oncol
; 56(2): 238-247, 2022 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35575587
6.
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
J Clin Oncol
; 38(27): 3138-3149, 2020 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32678716
7.
Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer.
Klin Onkol
; 32(Supplementum2): 24-30, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31409078
8.
Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.
Klin Onkol
; 32(Supplementum2): 31-35, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31409079
9.
Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Klin Onkol
; 32(Supplementum2): 6-13, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31409076
10.
[A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors]. / Výsledky retrospektivní analýzy cílené lécby metastatického karcinomu prsu trastuzumabem v MOU. Identifikace prediktivních faktoru.
Klin Onkol
; 21(6): 348-58, 2008.
Artículo
en Cs
| MEDLINE | ID: mdl-19382598
11.
MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
Diagn Pathol
; 7: 31, 2012 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-22439831
12.
Genetic and preventive services for hereditary breast and ovarian cancer in the czech republic.
Hered Cancer Clin Pract
; 4(1): 3-6, 2006 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20222996
Resultados
1 -
12
de 12
1
Próxima >
>>